In vitro effects of MYCN sense and antisense expression in MYCN-amplified human neuroblastoma cells

被引:0
|
作者
Kavallaris, M [1 ]
Gardaneh, M [1 ]
Cheung, B [1 ]
Camacho, ML [1 ]
Hocker, JE [1 ]
Norris, MD [1 ]
Haber, M [1 ]
Marshall, GM [1 ]
机构
[1] Sydney Childrens Hosp, Childrens Canc Res Inst, Randwick, NSW 2031, Australia
关键词
MYCN; neuroblastoma; antisense RNA;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Amplification of the MYCN oncogene is a strong predictor of treatment failure and chemo-resistance in childhood neuroblastoma. Stable expression of two partial MYCN gene fragments in antisense orientation reduced Mycn protein expression in an MYCN-amplified neuroblastoma tumor cell line, however; antisense cells did not exhibit an increased in vitro sensitivity to cytotoxic ol differentiating agents. In contrast, partial MYCN sense transfectants exhibited increased resistance to cytotoxic drugs. These data suggest that the chemo-resistance of MYCN-amplified neuroblastoma cells is complex, and may be due to factors additional to Mycn protein expression.
引用
收藏
页码:1793 / 1797
页数:5
相关论文
共 50 条
  • [31] Exploring the relationship between metabolism and the epigenome in MYCN-amplified neuroblastoma
    Dalton, Krista M.
    Lochmann, Timothy L.
    Coon, Colin
    Calbert, Marissa L.
    Dozmorov, Mikhail
    Shock, Lisa
    Koblinski, Jennifer
    Faber, Anthony C.
    CANCER RESEARCH, 2024, 84 (06)
  • [32] Targeting Ornithine Decarboxylase Impairs Development of MYCN-Amplified Neuroblastoma
    Rounbehler, Robert J.
    Li, Weimin
    Hall, Mark A.
    Yang, Chunying
    Fallahi, Mohammad
    Cleveland, John L.
    CANCER RESEARCH, 2009, 69 (02) : 547 - 553
  • [33] EXOSOMES FROM MYCN-AMPLIFIED NEUROBLASTOMA CONTAIN ONCOGENIC MICRORNAS
    Flaegstad, T.
    Haug, B. H.
    Hald, O.
    Utnes, P.
    Lokke, C.
    Einvik, C.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S329 - S329
  • [34] Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma
    Øyvind H. Hald
    Lotte Olsen
    Gabriel Gallo-Oller
    Lotta Helena Maria Elfman
    Cecilie Løkke
    Per Kogner
    Baldur Sveinbjörnsson
    Trond Flægstad
    John Inge Johnsen
    Christer Einvik
    Oncogene, 2019, 38 : 2800 - 2813
  • [35] Striking Dichotomy in Outcome of MYCN-Amplified Neuroblastoma in the Contemporary Era
    Kushner, Brian H.
    Modak, Shakeel
    Kramer, Kim
    LaQuaglia, Michael P.
    Yataghene, Karima
    Basu, Ellen M.
    Roberts, Stephen S.
    Cheung, Nai-Kong V.
    CANCER, 2014, 120 (13) : 2050 - 2059
  • [36] Synthetic lethal genes in MYCN-amplified neuroblastoma cells and their potential for therapeutic application
    Kiyonari, Shinichi
    Kadomatsu, Kenji
    CANCER SCIENCE, 2018, 109 : 1028 - 1028
  • [37] Exploit the zebrafish to study lymphocyte infiltration in MYCN-amplified neuroblastoma
    Qin, Xiaodan
    Lam, Andrew
    Feng, Hui
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [38] Inhibitors of Ribosome Biogenesis Repress the Growth of MYCN-Amplified Neuroblastoma
    Olsen, L.
    Hald, O.
    Gallo-Oller, G.
    Elfmann, L.
    Lokke, C.
    Kogner, P.
    Sveinbjornsson, B.
    Flaegstad, T.
    Johnsen, J. I.
    Eivik, C.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S337 - S337
  • [39] MYCN immunohistochemistry as surrogate marker for MYCN-amplified spinal ependymomas
    Mohan, Divya
    Nambirajan, Aruna
    Malik, Rafat
    Sharma, Agrima
    Suri, Vaishali
    Kaur, Kavneet
    Doddamani, Ramesh
    Garg, Ajay
    Gupta, Subhash
    Mallick, Supriya
    Sharma, Mehar Chand
    HUMAN CELL, 2024, 37 (03) : 704 - 713
  • [40] The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo
    Faisal, Amir
    Vaughan, Lynsey
    Bavetsias, Vassilios
    Sun, Chongbo
    Atrash, Butrus
    Avery, Sian
    Jamin, Yann
    Robinson, Simon P.
    Workman, Paul
    Blagg, Julian
    Raynaud, Florence I.
    Eccles, Suzanne A.
    Chesler, Louis
    Linardopoulos, Spiros
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (11) : 2115 - 2123